Biogen Shares Reach 52-Week High on Alzheimer’s Therapy Sales Surge
Biogen’s shares reached a 52-week high on February 8, propelled by a significant uptick in Alzheimer’s therapy sales driven by improved patient uptake and broader insurance coverage. The rally highlights renewed investor confidence in the drug’s commercial momentum and potential for future revenue growth.
1. Stock Surge and Sales Jump
On February 8, Biogen shares surged to a 52-week peak following a notable increase in Alzheimer’s therapy sales. Improved patient uptake and expanded insurance coverage underpinned the revenue boost, reflecting strengthened commercial performance and bolstered investor sentiment.
Related News
AMZN
AWS Faces Challenge as Nvidia Forecasts $91B Q3 Sales, Musk Eyes 2028 Space Data Centers
AMZN•
PII
Polaris Launches $9,999 RANGER 500 and Installs 8,000 m² Solar Array
PII•
ODV
Osisko Development Raises US$275M via 4.125% Convertible Notes with 25% Premium
ODV•
GOOGL
Alphabet Executes Record Yen Bond Sale as Google Secures 9.7 GWh AI Storage Contracts
GOOGL•
FDS
Nvidia Q1 Revenue Soars 85% to $81.6B as Buyback Approved
FDS•
Sources
F